Palanisamy Satheesh Kumar, Rajendran N M, Marino Angela
Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98166, Messina, Italy.
Key Laboratory of Engineering Plastics and Beijing National Laboratory for Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, China.
Nat Prod Bioprospect. 2017 Feb;7(1):1-111. doi: 10.1007/s13659-016-0115-5. Epub 2017 Jan 17.
This present study reviewed the chemical diversity of marine ascidians and their pharmacological applications, challenges and recent developments in marine drug discovery reported during 1994-2014, highlighting the structural activity of compounds produced by these specimens. Till date only 5% of living ascidian species were studied from <3000 species, this study represented from family didemnidae (32%), polyclinidae (22%), styelidae and polycitoridae (11-12%) exhibiting the highest number of promising MNPs. Close to 580 compound structures are here discussed in terms of their occurrence, structural type and reported biological activity. Anti-cancer drugs are the main area of interest in the screening of MNPs from ascidians (64%), followed by anti-malarial (6%) and remaining others. FDA approved ascidian compounds mechanism of action along with other compounds status of clinical trials (phase 1 to phase 3) are discussed here in. This review highlights recent developments in the area of natural products chemistry and biotechnological approaches are emphasized.
本研究回顾了1994 - 2014年期间报道的海洋被囊动物的化学多样性及其药理学应用、海洋药物发现中的挑战和最新进展,重点介绍了这些标本产生的化合物的结构活性。迄今为止,在不到3000种的活被囊动物物种中,仅研究了5%,本研究涵盖了Didemnidae科(32%)、Polyclinidae科(22%)、Styelidae科和Polycitoridae科(11 - 12%),这些科展示出了数量最多的有前景的海洋天然产物。本文根据近580种化合物的出现情况、结构类型和报道的生物活性进行了讨论。抗癌药物是从被囊动物中筛选海洋天然产物的主要关注领域(64%),其次是抗疟疾药物(6%),其余为其他药物。本文还讨论了美国食品药品监督管理局批准的被囊动物化合物的作用机制以及其他化合物的临床试验状态(1期到3期)。本综述突出了天然产物化学领域的最新进展,并强调了生物技术方法。